The name Provention Bio Inc. (PRVB) should be kept on your radar

In the latest session, Provention Bio Inc. (NASDAQ: PRVB) closed at $8.92 down -1.33% from its previous closing price of $9.04. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 891540 shares were traded. PRVB stock price reached its highest trading level at $9.11 during the session, while it also had its lowest trading level at $8.69.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



For a deeper understanding of Provention Bio Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.60 and its Current Ratio is at 7.60. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.16.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on September 20, 2022, initiated with a Buy rating and assigned the stock a target price of $10.

SVB Leerink reiterated its Outperform rating for the stock on April 09, 2021, while the target price for the stock was revised from $26 to $16.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 18 when Palmer Ashleigh sold 24,165 shares for $10.27 per share. The transaction valued at 248,063 led to the insider holds 2,570,050 shares of the business.

Sessa Capital (Master), L.P. sold 3,000,000 shares of PRVB for $28,200,000 on Jan 18. The 10% Owner now owns 11,879,023 shares after completing the transaction at $9.40 per share. On Jan 18, another insider, Leon Francisco, who serves as the Chief Scientific Officer of the company, sold 24,015 shares for $10.27 each. As a result, the insider received 246,584 and left with 1,573,000 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 273.02 while its Price-to-Book (P/B) ratio in mrq is 5.13.

Stock Price History:

Over the past 52 weeks, PRVB has reached a high of $10.88, while it has fallen to a 52-week low of $3.18. The 50-Day Moving Average of the stock is 9.12, while the 200-Day Moving Average is calculated to be 6.00.

Shares Statistics:

For the past three months, PRVB has traded an average of 1.83M shares per day and 1.22M over the past ten days. A total of 83.12M shares are outstanding, with a floating share count of 81.80M. Insiders hold about 6.06% of the company’s shares, while institutions hold 48.80% stake in the company. Shares short for PRVB as of Oct 13, 2022 were 3.48M with a Short Ratio of 7.41M, compared to 2.75M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.27% and a Short% of Float of 4.58%.

Earnings Estimates

There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.37 and a low estimate of -$0.53, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.37 and low estimates of -$1.08.

Analysts are recommending an EPS of between -$1.58 and -$2.47 for the fiscal current year, implying an average EPS of -$1.9. EPS for the following year is -$1.62, with 8 analysts recommending between -$0.66 and -$2.26.

Revenue Estimates

A total of 7 analysts believe the company’s revenue will be $780k this quarter.It ranges from a high estimate of $1.6M to a low estimate of $400k. As of the current estimate, Provention Bio Inc.’s year-ago sales were $1.25M, an estimated decrease of -37.60% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $2.64M, an increase of 268.20% over than the figure of -$37.60% in the same quarter last year. There is a high estimate of $5.74M for the next quarter, whereas the lowest estimate is $700k.

A total of 8 analysts have provided revenue estimates for PRVB’s current fiscal year. The highest revenue estimate was $8.66M, while the lowest revenue estimate was $2.7M, resulting in an average revenue estimate of $4.31M. In the same quarter a year ago, actual revenue was $1.4M, up 209.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $56.49M in the next fiscal year. The high estimate is $166.9M and the low estimate is $10.52M. The average revenue growth estimate for next year is up 1,210.70% from the average revenue estimate for this year.